Pain Reduced With Target Muscle Reinnervation at Time of Amputation
10 Jan 2024
Clinical Result
WEDNESDAY, Jan. 10, 2024 -- For patients undergoing amputation, targeted muscle reinnervation (TMR) at the time of amputation improves pain scores and reduces the rate of neuroma formation, according to a study published in the January issue of Plastic and Reconstructive Surgery.
Evelyn G. Goodyear, from Ohio State University Wexner Medical Center in Columbus, and colleagues conducted a cross-sectional retrospective chart review involving patients undergoing TMR between 2015 and 2020 to examine symptomatic neuroma recurrence and neuropathic pain outcomes between cohorts undergoing TMR at the time of amputation (acute) versus TMR following symptomatic neuroma formation (delayed). One hundred five limbs were identified from 103 patients, including 73 and 32 acute and delayed TMR limbs, respectively.
The researchers found that 19 and 1 percent of the delayed and acute TMR groups had symptomatic neuromas recur in the distribution of original TMR, respectively. Overall, 85 percent of patients in the acute TMR group and 69 percent of patients in the delayed TMR group completed pain surveys. Of this subgroup, significantly lower phantom limb pain Patient-Reported Outcome Measurement Information System (PROMIS) pain interference, residual limb pain (RLP) PROMIS pain intensity, and RLP PROMIS pain interference scores were reported by acute TMR patients versus delayed TMR patients.
"These results highlight the promising role of TMR in the prevention of neuropathic pain and neuroma formation when performed at the time of amputation," the authors write.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.